Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
20 Cards in this Set
- Front
- Back
Celebrex indication w/ CRC
|
FDA approved to decrease number of polyps in pts w/ FAP (familial adenomatosis polyposis)
|
|
ACS screening guidelines:
average risk |
starting age is 50.
colonoscopy q 10 yrs or sigmoidoscopy, barium enema q5 yrs |
|
ACS screening guidelines:
family history |
age 35-40
|
|
ACS screening guidelines:
HNPCC (hereditary nonpolyposis colon cancer) |
age 30
|
|
ACS screening guidelines:
FAP |
age 12
|
|
CRC 1st stage outside colon
|
stage III- lymph node involvement
|
|
treatment- stage I & II
|
surgery alone, surveillance, adjuvant chemo????
|
|
treatment- stage III
|
surgery + adjuvant chemo
5-FU based chemo standard 6 mo chemo superior to surgery alone |
|
irinotecan in adjuvant treatment of CRC
|
no use in adjuvant treatment
|
|
Kras that cetuximab responds to
|
wild-type (non-mutant) Kras
|
|
continue bevacizumab after progression?
|
Yes- improves OS compared to no treatment or other treatment without bevacizumab
|
|
tumor marker for CRC
|
CEA - carcinoembryonic antigen
|
|
how to take capecitabine
|
with meals
|
|
DLT for capecitabine
|
hand/foot syndrome & diarrhea
|
|
catabolism of 5FU is by
|
DPD- dihydropyrimidine dehydrogenase
deficiency= increase tox |
|
bevacizumab CRC dose
|
5mg/kg q 14 d
|
|
enzyme responsible for breakdown of irinotecan
|
UGT1A1
|
|
active metabolite of irinotecan
|
SN-38
|
|
early diarrhea w/ irinotecan treatment is a cholinergic response treated with
|
atropine 0.25-1mg IV
|
|
panitumumab dose
|
6mg/kg q14d
|